BUZZ - Bristol-Myers Squibb discloses patient death in early autoimmune disease clinical trial; stock price drops

October 23 - ** Bristol Myers Squibb (BMY.N) shares fell 2.4%, closing at $61.47

** The company stated that after the data cutoff in an early-stage clinical trial, a patient experienced a fatal case of septic pneumonia.

** The company is testing its experimental cancer therapy, zolacabtagene autoleucel, in patients with highly active relapsing multiple sclerosis.

** Multiple sclerosis is an autoimmune disease that affects the central nervous system.

** The company said the trial enrolled a total of 66 patients, and the safety profile of the therapy was consistent with previously reported data.

** Including intraday fluctuations, the stock has risen 13.9% so far this year.

(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of this automated translation feature.)